Outlook Therapeutics is trading at $1.47 (-6.09%) following a sharp pullback from the previous session’s close, likely pressured by broader weakness across the biotechnology sector.
- The stock is tracking a wider 2.00% decline in the biotech sector as risk appetite softens for growth-oriented equities.
- There are no new company-specific developments to explain the move, with the market's primary focus remaining on the FDA decision window scheduled for later this month.